The Partners
Christopher Ogden
Chris Ogden is a Consultant Urologist at The Royal Marsden Hospital NHS Trust. Having completed his general urological training, Chris undertook two fellowship years in Urological Oncology at the Charing Cross Hospital and the Royal Marsden Hospital and visited leading Oncological Centres in the United States. He was appointed consultant Urologist at Northwick Park and St Mark’s Hospital NHS Trust for 6 years prior to his appointment at Chelsea and Westminster Hospital where he worked for 4 years. His specific interests lie in urological malignancy, ileo-orthotopic bladder substitution following radical cystectomy for invasive bladder cancer in men and women and both nerve sparing retro pubic and perineal radical prostatectomy. He also has an interest in minimally invasive techniques including laparoscopic surgery, robotics and cryotherapy of the prostate.
Chris has considerable research interests. His principal research interests have been in the molecular biology of bladder and prostate cancer. This research has led to the discovery of novel genes preferentially expressed in bladder and prostate cancer that may prove to be both a diagnostic and a therapeutic target. Chris has also been involved in the monoclonal targeting of oncological tumors in terms of staging urological malignancies and their treatment. His thesis was in the development of microwave technology for the treatment of prostatic disorders. He has also been involved in the investigation of the role of dentritic cell response in bladder cancer.
GMC No.2957661
Qualifications
1984 M.B.B.S. University of London
1989 F.R.C.S. Edinburgh
1990 F.R.C.S. England
1993 M.S. University of London
1995 F.R.C.S. Urology
1996 F.E.B.U.
Current Posts
Consultant Urologist, The Royal Marsden Hospital
Honorary Senior Lecturer, Imperial College of Science and Technology
Professional Experience
Consultant Urologist, The Royal Marsden Hospital, London (2002 - 2006)
Consultant Urologist & Clinical Lead of Urology, Northwick Park & St. Mark's Hospital (1996-2001)
The West London Urology Senior Registrar Training Scheme (1990-1994)
Travelling fellowship to the USA with Dr D Skinner, University of Southern California, Los Angeles; Dr P Walsh, John Hopkins Hospital, Baltimore ;Dr J Paulson, Duke University, North Carolina (1995)
Special Interests
Prior to his appointment as Uro-oncologist at Chelsea and Westminster Hospital, Chris developed an interest in urological oncology. Chris offers the Scardino modified Studer neo-bladder reconstructions following cystectomy, for both men and women resulting in excellent outcomes to date. Where appropriate, he offers the use of radical perineal prostatectomy in the treatment of organ confined prostate cancer as a minimally invasive alternative to nerve sparing retropubic prostatectomy which he also has extensive experience in. More recently he has developed the laparoscopic approach for uro-oncology and cryotherapy for prostate cancer.
Current University and Hospital Research Activities
In association with the Kenedy Gaulton Academic Unit of Medical & Community Genetics, and the Imperial College of Science Technology & Medicine, Chris has conceived and designed a research strategy to look into the link between developmental genes and urological malignancy. This has attracted three full research fellowship awards from the Royal College of Surgeons. The work has found an interesting link between PAX genes and prostate cancer leading to the filling and granting of a UK & US patent.
Other projects
Chris is also involved with other projects including:
Monoclonal antibody targeting of prostate cancer: A phase II open-label trial to evaluate intravenous 3622W94 Monoclonal Antibody for the treatment of prostate cancer.
Evaluation of primary and metastatic cancer of the prostate using radioimmunoscintigraphy with Indium-111 labelled CYT-356 a monoclonal antibody reactive with prostate cancer in association with Academic nuclear medicine department at St Mark's Hospital.
Currently he is actively researching the dentritic cell response in bladder cancer and BCG therapy. Human endoretrovirus and their relation to
prostate cancer.